Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant inetetamab + pertuzumab + toripalimab + paclitaxel in HER2-positive breast cancer
ChiCTR2500109920Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inetetamab, pertuzumab, toripalimab and paclitaxel in breast cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Total pathological complete response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
inetetamabpertuzumabtoripalimabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500109920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109920.